论文部分内容阅读
目的探讨抗幽门螺杆菌(Hp)治疗再发性腹痛(RAP)和慢性浅表性胃炎(CSG)的疗效及其必要性。方法选择本院符合RAP诊断的患儿118例,其中Hp感染52例;胃镜检查后确诊CSG120例,其中Hp感染58例。分别将其分为3组(Hp阴性组、抗Hp治疗组、未抗Hp治疗组),所有患儿治疗3个月,分别行胃镜检查、Hp检测和临床疗效判断,应用SPSS11.0软件进行统计学分析。结果CSG和RAP的发病与Hp感染与否均无关(Pa>0.05)。RAP抗Hp治疗组治疗前后疗效比较差异有统计学意义(χ2=6.74,P<0.05);CSG抗Hp治疗组治疗前后疗效比较差异有统计学意义(χ2=6.16,P<0.05)。结论CSG和RAP的发病与Hp感染无明确相关性,但CSG和RAP的患儿一旦明确有Hp感染,仍应予Hp根除治疗。
Objective To investigate the efficacy and necessity of anti-Helicobacter pylori (Hp) in the treatment of recurrent abdominal pain (RAP) and chronic superficial gastritis (CSG). Methods A total of 118 children diagnosed with RAP in our hospital were selected, of which 52 cases were Hp infection. After CSG, 120 cases were confirmed by CSG, of which 58 cases were Hp infection. The patients were divided into three groups (Hp negative group, anti-Hp treatment group and no anti-Hp treatment group). All patients were treated for 3 months. Gastroscopy, Hp detection and clinical curative effect were respectively evaluated. SPSS11.0 software Statistical analysis. Results The incidence of CSG and RAP was not related to Hp infection or not (Pa> 0.05). There was significant difference in curative effect between RAP anti-Hp treatment group before and after treatment (χ2 = 6.74, P <0.05). There was significant difference in curative effect between CSG anti-Hp treatment group before and after treatment (χ2 = 6.16, P <0.05). Conclusion There is no clear correlation between the incidence of CSG and RAP and Hp infection. However, Hp eradication should still be given once the children with CSG and RAP are clearly infected with Hp.